Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Hematologic Malignancy Reports
Published in: Current Hematologic Malignancy Reports 6/2019

Open Access 01-12-2019 | Tyrosine Kinase Inhibitors | Chronic Myeloid Leukemias (G Saglio, Section Editor)

Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

Author: Richard E. Clark

Published in: Current Hematologic Malignancy Reports | Issue 6/2019

Login to get access

Abstract

Purpose

In chronic myeloid leukaemia, tyrosine kinase inhibitor treatment is traditionally given continuously for life. However, these drugs produce excellent responses for many patients, and this is accompanied by survival that is close to normal. This has prompted studies of whether it is possible to stop treatment, thus achieving a treatment-free remission (TFR).

Recent Findings

Most TFR studies have focussed on abrupt cessation in patients with long-standing deep remissions, but recent data suggest that more gradual treatment de-escalation may improve TFR success, and that it may be possible to extend TFR attempts to patients who are in stable major molecular response but not necessarily MR4.

Summary

Further data are badly needed on TFR for patients whose remission is less than stable MR4 and on the importance of prior interferon-alpha treatment. Funding TFR trials in a disease with such an excellent outlook is an increasing challenge.
Literature
1.
Goldman JM, Baughan ASJ. Chronic granulocytic leukaemia: treatment. In: Goldman JM, Preisler HD, editors. Leukemias, Butterworth International Medical Reviews, vol. 8. London: Butterworth and Co. p. 239–65.
2.
Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C, et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol. 2002;20:214–20.PubMed
3.
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27.PubMedPubMedCentral
4.
Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60.PubMed
5.
Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–35.PubMed
6.
Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French sStop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.PubMed
7.
• Saussele S, Richter J, Hochhaus A, Mahon FX. The concept of treatment-free remission in chronic myeloid leukemia. Leukemia. 2016;30:1638–47 A useful review of earlier TFR studies.PubMedPubMedCentral
8.
• Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. 2016;128:17–23 A useful review of earlier TFR studies. PubMed
9.
• Cortes J, Rea D, Lipton JH. Treatment-free remission with first- and second-generation tyrosine kinase inhibitors. Am J Hematol. 2019;94:346–57 An excellent review of more recent TFR studies. PubMed
10.
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122:515–22.PubMed
11.
Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018;32:2572–9.PubMed
12.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.PubMed
13.
Réa D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129:846–54.PubMed
14.
•• Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–57 TFR study of over 700 patients, confirming earlier data and demonstrating deliverability of PCR at typical TFR levels in different labs across many European countries.PubMed
15.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4:e310–6.PubMed
16.
•• Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6:e375–83 British TFR study differing from others in that there is an initial 12 month de-escalation period of half- dose treatment, and also in the inclusion of 49 patients in stable MMR but not MR4.PubMed
17.
Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, et al. Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. Haematologica. 2019;104:1589–96 Comment by Schiffer CA. Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia – you can do this at home if you read the instructions. Haematologica 2019; 104: 1508–1511.PubMedPubMedCentral
18.
Hernández-Boluda JC, Pereira A, Pastor-Galán I, Alvarez-Larrán A, Savchuk A, Puerta JM, et al. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. Blood Cancer J. 2018;8:91.PubMedPubMedCentral
19.
Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90:910–4.PubMed
20.
Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101:717–23.PubMedPubMedCentral
21.
Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123:4403–10.PubMed
22.
Mahon F-X, Boquimpani C, Kim D-W, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168:461–70.PubMed
23.
Shah NP, Paquette R, Müller MC, Saussele S, Garcìa-Gutiérrez V, Jiménez-Velasco A, et al. Treatment-free remission in patients with chronic phase chronic myeloid leukemia and in stable deep molecular response to dasatinib - the Dasfree study. Blood. 2016;128:1895.
24.
Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18:353–60.PubMed
25.
Ross DM, Masszi T, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144:945–54.PubMedPubMedCentral
26.
Réa D, Rosti G, Cross NCP, Hellmann A, Niederwieser D, Pungolino E, Falzetti F, Pregno P, Orlandi EM, Almeida A, Illes A, Sagues M, Haenig J, Supekar S, Shah S, Saglio G, Steegmann JL, Baccarani M. ENESTPath: a phase 3 study to assess the effect of nilotinib treatment duration on treatment-free remission in patients with chronic myeloid leukemia in chronic phase previously treated with imatinib: 24-month analysis of the first 300 patients in the induction/consolidation phase. Presented at the American Society of Hematology Annual Meeting, 2016.
27.
Ritchie EK, Catchatourian R, Klisovic RB, Pinilla-Ibarz J, Deininger MW, Erba HP, Radich JP, Savona MR, Dautaj I, Purkayastha D, Habucky K, Mauro MJ. Results from ENESTgoal: a phase 2 study of treatment-free remission in patients with chronic myeloid leukemia in chronic phase who switched from imatinib to nilotinib. Presented at the American Society of Hematology Annual Meeting, 2017.
28.
Burchert A, Saussele S, Eigendorff E, Müller MC, Sohlbach K, Inselmann S, et al. Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Leukemia. 2015;29:1331–5.PubMed
29.
Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, et al. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. Br J Haematol. 2019. https://​doi.​org/​10.​1111/​bjh.​15894[Epub ahead of print].
30.
Faber E, Divoká M, Skoumalová I, Novák M, Marešová I, Mičová K, et al. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma. 2016;57:370–5.PubMed
31.
Fassoni AC, Baldow C, Roeder I, Glauche I. Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data. Haematologica. 2018;103:1825–34.PubMedPubMedCentral
32.
Kinstrie R, Horne GA, Morrison H, Irvine D, Munje C, Castañeda EG, Moka HA, Dunn K, Cassels JE, Parry N, Scott MT, Clark RE, Holyoake TL, Wheadon H, Copland M. CD93 is selectively upregulated on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy. Submitted for publication.
33.
Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53:2351–61.PubMed
34.
Rojas JM, Knight K, Watmough S, Bell J, Wang L, Callaghan T, et al. BCR-ABL peptide vaccination in healthy subjects: immunological responses are equivalent to those in chronic myeloid leukaemia patients. Leukaemia Research. 2011;35:369–72.
35.
Austin GM, Knight K, Bell J, Carter A, Heartin E, Watson D, et al. The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial. Br J Haematol. 2019;185:791–3.PubMed
36.
Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108–16.PubMed
37.
Schütz C, Inselmann S, Saussele S, Dietz CT, Müller MC, Eigendorff E, et al. Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Leukemia. 2017;31:829–36 with erratum at Leukemia 2018; 32: 1054.PubMed
38.
Réa D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368–77.PubMedPubMedCentral
39.
Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer NetwJ Natl Compr Canc Netw. 2018;16:1108–35.
40.
Hochhaus A, Saussele S, Rosti G, Mahon F-X, Janssen JJWM, Hjorth-Hansen H, Richter J, Buske C, on behalf of the ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncol. 2017; 28, suppl 4: iv41-iv51. [Corrigendum at Annals of Oncol. 2016; 29 supplement 4: iv261].
41.
Goh HG, Kim YJ, Kim DW, Kim HJ, Kim SH, Jang SE, et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma. 2009;50:944–51.PubMed
42.
Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014;55:2879–86.PubMed
43.
Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, Räsänen A, et al. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014;92:413–20.PubMed
44.
Gottschalk A, Glauche I, Clark RE, Roeder I. Individual response of CML patients to TKI dose reduction can reliably identify patients with high risk of molecular relapse after treatment cessation. Presented at the European Haematology Association annual meeting, Amsterdam, June 2019, and submitted for publication.
45.
Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, et al. E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy. Haematologica. 2017;102:e297–9.PubMedPubMedCentral
46.
D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, et al. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. Cancer. 2019;125:1674–82.PubMed
47.
Alikian M, Gale RP, Apperley JF, Foroni L. Molecular techniques for the personalised management of patients with chronic myeloid leukaemia. Biomol Detect Quantif. 2017;11:4–20.PubMedPubMedCentral
48.
Richter J, Söderlund S, Lübking A, Dreimane A, Lotfi K, Markevärn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821–3.PubMed
49.
Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Reply to J. Richter et al. J Clin Oncol. 2014;32:2823–5.PubMed
50.
Berger MG, Pereira B, Rousselot P, Cony-Makhoul P, Gardembas M, Legros L, Escoffre-Barbe M, Nicolini FE, Saugues S, Lambert C, Réa D, Guerci-Bresler A, Giraudier S, Guilhot J, Saussele S, Mahon FX; (France Intergroupe des Leucémies Myéloïdes Chroniques). Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome. Br J Haematol 2019. doi: https://​doi.​org/​10.​1111/​bjh.​16083. [Epub ahead of print].PubMed
51.
• Kota V, Atallah E. Musculoskeletal pain in patients with chronic myeloid leukemia after tyrosine kinase inhibitor therapy cessation. Clin Lymphoma Myeloma Leuk. 2019. A recent review of the TKI withdrawal syndrome.
52.
Katagiri S, Tauchi T, Ando K, Okabe S, Gotoh M, Ohyashiki K. Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia. Leuk Res Rep. 2017;7:33–5.PubMedPubMedCentral
53.
Diab M, Schiffer CA. The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors. Leuk Res. 2019;79:1–2.PubMed
54.
Shanmuganathan N, Braley JA, Yong ASM, Hiwase DK, Yeung DT, Ross DM, et al. Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. 2019;134:85–9.PubMed
55.
Zang DY, Lee WS, Mun Y-C, Do YR, Oh S, Lee S-E, et al. Long-term follow-up after treatment discontinuation in patients with chronic myeloid leukemia: the Korean imatinib discontinuation (KID) study. Blood. 2018;132:4252.
56.
Villemagne Sanchez LA, O'Callaghan C, Gough K, Hall K, Kashima Y, Seymour JF, et al. Patient perceptions of treatment-free remission in chronic myeloid leukemia. Leuk Lymphoma. 2018;59:406–15.PubMed
57.
Sogawa R, Kimura S, Yakabe R, Mizokami Y, Tasaki M, Sueoka-Aragane N, et al. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia. Int J Clin Oncol. 2018;23:974–9.PubMed
58.
Jiang Q, Yu L, Gale RP. Patients’ and hematologists’ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia. J Cancer Res Clin Oncol. 2018;144:735–41.PubMed
Metadata
Title
Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice
Author
Richard E. Clark
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Hematologic Malignancy Reports / Issue 6/2019
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-019-00548-2

Other articles of this Issue 6/2019

Current Hematologic Malignancy Reports 6/2019 Go to the issue

Myelodysplastic Syndromes (M Savona, Section Editor)

Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO

Acute Myeloid Leukemias (H Erba, Section Editor)

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Chronic Myeloid Leukemias (G Saglio, Section Editor)

Early Management of CML

Acute Myeloid Leukemias (H Erba, Section Editor)

Health-Related Quality of Life and Treatment of Older Adults with Acute Myeloid Leukemia: a Young International Society of Geriatric Oncology Review Paper

Myelodysplastic Syndromes (M Savona, Section Editor)

The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS)

Chronic Myeloid Leukemias (G Saglio, Section Editor)

What Does Chronic Myeloid Leukaemia Tell Us About Other Leukaemias?

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits